Categories: Other
Description:
Active surveillance for low-risk prostate cancer is a structured monitoring strategy that delays or avoids treatment unless the cancer shows signs of progression.
Typical follow-up includes:
-PSA testing: every 6 months
-Digital rectal exam (DRE): every 12 months
-Prostate biopsy: typically within 12–18 months after diagnosis, then every 2–5 years depending on risk factors and findings
-Multiparametric MRI: may be used periodically, especially if biopsy findings are ambiguous
If there is evidence of grade progression, rapid PSA rise, or increased tumor volume, curative treatment like surgery or radiation may be recommended.
Treatment For:
AI generated Summary: Based on the single review provided, Active Surveillance appears to be a highly effective treatment for Low Risk Prostate Cancer. The review suggests that the annual risk of progression is low (5-10% per year) and the likelihood of metastasis or prostate cancer-specific mortality is extremely low over long-term follow-up when using Active Surveillance.
Active surveillance is preferred for low-risk prostate cancer because the annual risk of progression is low (about 5–10% per year), and the likelihood of metastasis or prostate cancer-specific mortality is extremely low over long-term follow-up.
The information, including but not limited to, text, graphics, images and other material contained on this website/app are for informational purposes only. No material on this site/app is intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition or treatment and before undertaking a new health care regimen, and never disregard professional medical advice or delay in seeking it because of something you have read on this website/app.
Copyright © 2025,Curbside and related marks are registered trademarks of Curbside Tech Inc.
